Teva Pharmaceutical Industries (NYSE:TEVA) Given New $45.00 Price Target at Truist Financial

Teva Pharmaceutical Industries (NYSE:TEVA) had its target price upped by Truist Financial from $42.00 to $45.00 in a research report sent to investors on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other research firms have also recently issued reports on TEVA. Jefferies Financial Group boosted their target price on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Piper Sandler reiterated an “overweight” rating and issued a $41.00 target price (up from $40.00) on shares of Teva Pharmaceutical Industries in a research note on Wednesday, March 4th. Bank of America boosted their target price on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 9th. Barclays boosted their target price on shares of Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an “overweight” rating in a research note on Friday, January 30th. Finally, The Goldman Sachs Group upped their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Teva Pharmaceutical Industries currently has a consensus rating of “Moderate Buy” and a consensus target price of $41.56.

Teva Pharmaceutical Industries Stock Performance

TEVA opened at $35.03 on Thursday. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.04 and a quick ratio of 0.80. The firm has a fifty day moving average price of $31.15 and a 200 day moving average price of $29.33. Teva Pharmaceutical Industries has a 1 year low of $14.99 and a 1 year high of $37.35. The stock has a market cap of $40.28 billion, a P/E ratio of 26.34, a P/E/G ratio of 3.12 and a beta of 0.76.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 44.86%. The firm had revenue of $3.98 billion during the quarter. Equities research analysts anticipate that Teva Pharmaceutical Industries will post 2.6 earnings per share for the current year.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Richard Daniell sold 17,295 shares of the company’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total transaction of $547,732.65. Following the completion of the transaction, the executive vice president directly owned 85,755 shares in the company, valued at approximately $2,715,860.85. This represents a 16.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Eliyahu Sharon Kalif sold 345,810 shares of the company’s stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $33.64, for a total transaction of $11,633,048.40. Following the transaction, the executive vice president owned 57,478 shares of the company’s stock, valued at $1,933,559.92. This represents a 85.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 920,901 shares of company stock valued at $30,056,789 in the last three months. Company insiders own 0.54% of the company’s stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

A number of large investors have recently modified their holdings of TEVA. AQR Capital Management LLC grew its holdings in shares of Teva Pharmaceutical Industries by 24.6% during the first quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock worth $368,000 after buying an additional 4,732 shares in the last quarter. Focus Partners Wealth grew its holdings in shares of Teva Pharmaceutical Industries by 4.5% during the first quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock worth $616,000 after buying an additional 1,739 shares in the last quarter. Franklin Resources Inc. purchased a new stake in shares of Teva Pharmaceutical Industries during the second quarter worth $255,000. Flow Traders U.S. LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the second quarter worth $238,000. Finally, Cerity Partners LLC grew its holdings in shares of Teva Pharmaceutical Industries by 2.9% during the second quarter. Cerity Partners LLC now owns 45,837 shares of the company’s stock worth $768,000 after buying an additional 1,291 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

More Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q1 results beat and fundamentals: Teva reported Q1 revenue of ~$4.0B and EPS that topped estimates, driven by branded drugs (Austedo, Ajovy, Uzedy). Management reiterated FY guidance in line with consensus, supporting the near‑term re‑rating thesis. Reuters: Teva beats Q1 profit estimates
• Positive Sentiment: Acquisition expands pipeline: Teva agreed to acquire Emalex (deal reports cite up to ~$900M) to add ecopipam, an NDA‑ready first‑in‑class pediatric Tourette therapy — a strategic, late‑stage asset that supports longer‑term growth. GlobeNewswire: Teva to acquire Emalex
• Positive Sentiment: Multiple analyst upgrades and higher targets: Truist raised its price target to $45 (buy), UBS to $42 (buy), JPMorgan to $40 (overweight), and Piper Sandler reaffirmed overweight at $42 — implying double‑digit upside from current levels and likely supporting buying interest. Benzinga: analyst actions
• Positive Sentiment: Institutional / financing interest: Reports of a $400M Blackstone commitment/financing and unusually large call option activity signal bullish institutional positioning. Fool: Blackstone bet
• Neutral Sentiment: Sustainability milestone: Teva said it met all sustainability‑linked bond targets (~$7.5B of bonds), which reduces ESG-related refinancing risk and links some financial outcomes to ESG KPIs. GlobeNewswire: Healthy Future Report
• Neutral Sentiment: Market research mention: Teva appears in industry reports as a leading player in oral solid dosage CMOs, which is positive for strategic positioning but not an immediate stock catalyst. ResearchAndMarkets / Yahoo
• Negative Sentiment: Generics weakness and near‑term headwinds: Management noted weaker generics revenue (including lenalidomide capsule impacts), a factor that trims margin visibility and may limit near‑term upside despite branded growth. GlobeNewswire: Q1 results

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.